Evidence map›Paper›PMID 33879509›Full record

ArticleOpen heart2021

A nutraceutical strategy for downregulating TGFβ signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.

James J DiNicolantonio, Mark F McCarty, Jorge Barroso-Aranda, Simon Assanga, Lidianys Maria Lewis Lujan, James H O'Keefe

Open access · goldAbstract readEditorial
In one paragraph

Article in Open heart, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

James J DiNicolantonioPreventive Cardiology, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA jjdinicol@gmail.com.ORCID 0000-0002-7888-1528
Mark F McCartyCatalytic Longevity, Encinitas, California, USA.
Jorge Barroso-ArandaClinica Libre de Adicciones, Tijuana, Mexico.
Simon AssangaDepartment of Research and Postgraduate Studies in Food, University of Sonora, Sonora, Mexico.
Lidianys Maria Lewis LujanDepartment of Research and Postgraduate Studies in Food, University of Sonora, Sonora, Mexico.
James H O'KeefeUniversity of Missouri-Kansas City, Saint Lukes Mid America Heart Institute, Kansas City, Missouri, USA.ORCID 0000-0002-3376-5822
Saint Luke's Hospital · USUniversidad de Sonora · MXCatalytic Longevity · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Dietary SupplementsPulmonary FibrosisCOVID-19Down-RegulationDrug DiscoveryFibroblastsGene Expression ProfilingHumansResearch DesignSARS-CoV-2Signal TransductionTransforming Growth Factor betaTransforming Growth Factor betacarotid artery diseasescoronary angiographyCOVID-19echocardiography

Identifiers

PMID33879509
PMCPMC8061562
OpenAlexW3153238101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.